BMY Short Volume
Bristol-Myers Squibb Company (BMY) operates in the Healthcare sector, specifically the Drug Manufacturers - General industry, with a market capitalization near $130.12B, listed on NYSE, employing roughly 32,500 people, carrying a beta of 0.23 to the broader market. Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. Led by Christopher S. Boerner, public since 1972-06-01.
Short volume measures the number of shares sold short on a given day as reported by FINRA. Tracking short volume relative to total volume helps identify unusual bearish sentiment or short-squeeze potential.
- Latest Date
- 2026-08-14
- Short Volume
- 1.2M
- Total Volume
- 2.4M
- Short %
- 51.36%
- 30-Day Avg Short %
- 50.98%
Showing 30 days of FINRA short volume data for Bristol-Myers Squibb Company.
Learn how short volume is reported and how to read the data →
Frequently asked BMY short volume questions
- What is the daily BMY short volume?
- As of Aug 14, 2026, Bristol-Myers Squibb Company (BMY) short volume is 1.2M shares against 2.4M total reported volume, or 51.36% short-side. Short volume measures shares sold short during the day; it is flow, not inventory.
- How is BMY short volume reported?
- FINRA publishes the Daily Short Sale Volume File for trades reported to FINRA TRFs and the FINRA/Nasdaq ADF on a T+1 basis. The headline figure is the count of shares that printed at the short-sale or short-exempt tick across all reporting venues for the symbol; each exchange separately publishes its own daily short-sale data file.
- What does BMY short volume tell options traders?
- Daily short-sale flow is one input that helps disambiguate dealer-hedging activity from directional bear flow when the chain shows fresh customer call inventory. It is not a clean MM-only proxy: the headline number mixes directional shorting, options-MM delta-hedging, ETF-creation arbitrage, and convertible-arb hedging. Cross-check against gamma-exposure and OI changes for a cleaner read.